PLUS THERAPEUTICS INC (NASDAQ: PSTV)

1. Introduction

Plus Therapeutics, Inc. is a Houston-based, clinical-stage pharmaceutical company developing targeted radiotherapeutics for rare and difficult-to-treat cancers of the central nervous system (CNS). Founded in 2019 (formerly Cytori Therapeutics), Plus Therapeutics utilizes nanoliposome-based delivery of Rhenium radioisotopes to enhance radiation doses to tumors while minimizing exposure to healthy tissue.

2. Corporate Structure

• Headquarters: Houston, Texas, United States
• Founded: 2019 (company renamed to Plus Therapeutics in 2019)
• Company size: 11–50 employees
• Type: Public (Nasdaq: PSTV)
• Key Leadership:
  • Marc H. Hedrick, M.D. — President & Chief Executive Officer
  • Kyle Guse — Chief Financial Officer & General Counsel
  • Michael Rosol, Ph.D. — Chief Development Officer (appointed March 2025)
  • Russell Bradley — President & General Manager, CNSide Diagnostics (appointed March 2025)
  • Jonathan Stein, M.D. — Medical Director, CNSide Diagnostics (appointed March 2025)

3. Recent Developments and News

Stock Performance (as of June 2, 2025)

Metric	Value
Share price	$0.3903 (+36.04%)
Volume	10,931,976 shares
52-Week Range	$0.24 – $2.67
Market Capitalization	$4.79 M
Beta (5Y Monthly)	0.88

Financial Reporting and SEC Filings

• March 27, 2025: Press release reporting Q4 2024 and full-year 2024 financial results.
• May 30, 2025: Filed Form 10-Q for the quarter ended March 31, 2025, and Form 8-K covering items 2.02 (Results of Operations) and 9.01 (Financial Statements and Exhibits).

Q4 2024 & Full-Year 2024 Highlights (reported March 27, 2025)

• Cash & Investments: $3.6 M (Dec 31, 2024) vs. $8.6 M (Dec 31, 2023)
• Grant Revenue: $5.8 M (2024) vs. $4.9 M (2023) from the Cancer Prevention & Research Institute of Texas for support in the leptomeningeal metastases (LM) program
• Operating Loss: $14.7 M (2024) vs. $13.3 M (2023)
• Net Loss: $13.0 M or $(1.95)/share (2024) vs. $13.3 M or $(4.24)/share (2023)
• Financing: $15.0 M raised in a private placement; $2.0 M advance on existing $17.6 M CPRIT grant

Clinical and Commercial Milestones

• Brand Name Agreement: FDA agreement on the name REYOBIQ™ (Rhenium Re186 Obisbemeda)
• Publication: Phase 1 trial results published in Nature Communications, indicating that patients receiving more than 100 Gy achieved a median overall survival of 17 months
• Orphan Drug Designation: Granted by FDA for LM in lung cancer patients
• ReSPECT-LM: Completed single-dose Phase 1 trial and established Phase 2 doses; data presented at the Society for Neuro-Oncology Annual Meeting (2024) and San Antonio Breast Cancer Symposium (2024)
• Supply Agreement: Expanded partnership with Telix IsoTherapeutics Group for supply of cGMP Rhenium-186

Upcoming Events

• May 9–10, 2025: Oral presentation at the Nuclear Medicine & Neuro-Oncology Symposium (Vienna, Austria)
• August 14–16, 2025: Key Opinion Leader symposium at the SNO/ASCO CNS Metastases Conference (Baltimore, MD)
• 2025 Milestones:
  • Commercial launch of the CNSide diagnostic platform
  • Completion of ReSPECT-LM Phase 1 multiple-dose cohort 1 enrollment
  • End-of-Phase 1 FDA meeting for ReSPECT-LM
  • Completion of ReSPECT-GBM Phase 2 enrollment
  • IND approval for ReSPECT-PBC (pediatric brain cancer) Phase 1/2 trial

4. Financial and Strategic Analysis

Key Financial Metrics (TTM as of May 30, 2025)

Metric	Value
Revenue	$5.82 M
Net Loss	$12.98 M
EPS	–2.34
Profit Margin	–222.84%
Total Cash (mrq)	$3.61 M
Average Volume	17.8 M shares

• Liquidity: Cash burn is supported by grants and private placements, providing a runway into 2026
• R&D Focus: A significant portion of expenses is directed toward ReSPECT clinical trials and the CNSide diagnostic validation
• Partnerships: Collaborations with Telix IsoTherapeutics Group for isotope supply and with CPRIT for grant funding
• Capital Structure: Market cap of $4.79 M; no debt/equity ratio disclosed

5. Market Position and Industry Context

• Sector: Pharmaceutical manufacturing, particularly focused on radiotherapeutics and nanomedicine
• Competitive Landscape: Competes with other clinical-stage companies developing radiopharmaceuticals for CNS cancers along with standard chemotherapies utilizing convection-enhanced delivery
• Regulatory Environment: Needs FDA approvals for both diagnostic (CNSide) and therapeutic (REYOBIQ) products; orphan drug designations provide development incentives
• Market Demand: Approximately 12,900 glioblastoma cases are diagnosed annually in the U.S.; there are currently no FDA-approved treatments for leptomeningeal metastases; pediatric brain tumors account for approximately 26% of childhood cancers

tl;dr

• On June 2, 2025, PSTV shares closed at $0.3903 (+36.04%) on a volume of 10.9 M shares.
• March 27, 2025 results indicated $3.6 M in cash, $14.7 M in operating loss, and $15 M from financings.
• Clinical progress for REYOBIQ™ includes published Phase 1 data in Nature Communications and FDA orphan designation for leptomeningeal metastases.
• The CNSide diagnostic platform is expected to commercially launch in the U.S. in 2025.
• Key upcoming milestones include multiple-dose ReSPECT-LM enrollment, completion of ReSPECT-GBM Phase 2, and IND filing for pediatric trials.